Mirador Analytics extended Board of Directors.
Mirador Analytics has bolstered its Board of Directors with the addition of two life sciences executives from Thomson Reuters Scientific & Healthcare and Kyowa Kirin International.
Mirador Analytics, the leading HIPAA Expert Determination provider, recently announced the extension of its Board of Directors, adding two prominent life sciences former executives, Shahir Kassam-Adams, Corporate Development at Datavant, former Executive Vice President of Thomson Reuters Scientific & Healthcare, and Dr. Tom Stratford, CEO of Kelso Pharma, former CEO and President of Kyowa Kirin International. The extended Board, which consists of five members, also includes Jamie Blackport, Founder, CEO, and President; Jamie Gray, Chief Operating Officer; and Chris Watson, Head of IT & Security, all of Mirador Analytics.
The two new board members bring broad and deep expertise to the company, which will help guide its future strategy and growth.
Kassam-Adams was co-founder of Universal Patient Key (UPK) – now a part of Datavant. In addition, he has been an operator or early investor in multiple health care technology-enabled start-ups and companies, including Aileron Solutions, Social Safeguard, TGaS, Decision Resources Group (DRG), and Thomson Reuters Scientific & Healthcare. Shahir has an MS in Computer Science from Johns Hopkins University and an MBA from the Wharton School of the University of Pennsylvania.
Stratford is a highly experience life sciences executive with a 25+ year track record in establishing and building businesses across Europe, the Middle East, and the USA. He was one of the first early employees in ProStrakan as it grew to be a public company. Following the acquisition by Kyowa Kirin, Tom spent nine years leading the European and US teams as CEO/President with a combined turnover approaching $1bn. Tom currently serves as a NED for Axol Biosciences and CEO of Kelso Pharma.
Blackport has a 20+ year commercial and medical affairs global pharmaceutical career where he specialized in successfully helping small and mid-sized biopharma companies commercially develop, transact, and launch products worldwide. Jamie led the International Marketing and Medical Affairs of Kyowa Kirin International and AstraZeneca. He started Mirador Analytics with his fellow founders as they recognized health care organizations needed support to realize the full potential of their data and analyses. Offering that support would, in turn, help support innovation and growth in the industry and advance global health care.
About Mirador Analytics
Mirador Analytics supports organizations across the health care ecosystem to ensure the privacy of individuals is protected through expert evaluation of data de-identification and the use of proprietary software solutions. Mirador Analytics aims to achieve high levels of privacy for individuals while maximizing data utility to allow for innovation, efficiency, and development in health care. For more information, visit www.miradoranalyitcs.com
Jamie Blackport, firstname.lastname@example.org
Eszter Vuity, email@example.com
Syntegra Partners with Mirador Analytics to Certify Industry-Wide Privacy Metrics for Synthetic Data
SAN FRANCISCO, CA and WILMINGTON, DE, [Date TBD] – Today, Syntegra, a leader in synthetic healthcare data generation, and Mirador Analytics, the leading HIPAA expert determination provider, announced a partnership to certify Syntegra’s metrics for validating the privacy of synthetic data. This partnership is another step forward in both companies’ broader goal of enabling easier, faster and safer access to healthcare data to advance research efforts.
Syntegra is working with Mirador to review and certify Syntegra’s privacy techniques used to validate that their synthetic data fully protects patient privacy, ensuring no patient can be re-identified via the synthetic data. Once the project is complete later this year, the companies plan to publish materials that will support application and understanding of these privacy-preserving techniques for a wider audience to aid industry thought-leadership/guidelines.
Syntegra is leading the creation of privacy metrics for synthetic data, enabling synthetic healthcare data to be clearly assessed by any organization within a risk and privacy governance structure they already understand. Through this work, Syntegra and Mirador are paving the way for standard, industry-wide metrics to ensure patient privacy while enabling greater usage and value of healthcare data.
Maintaining patient privacy is paramount, but the industry must discover better ways of securely sharing and accessing patient data to advance the field of medicine, and synthetic data is an important mechanism to address this need. Rather than assuming synthetic data is inherently private simply because it’s synthetic, Syntegra is taking it a further step by partnering with Mirador to certify their metrics. This is particularly important when synthetic data is generated from actual health records.
“Any medical innovation requires evidence, and evidence requires data. To improve outcomes, it is imperative that we find new ways of leveraging healthcare data while protecting patient privacy,” said Michael D. Lesh, MD, founder and CEO of Syntegra. “We’re thrilled to partner with Mirador to help prove that Syntegra-generated synthetic data successfully prevents disclosure of patient information.”
"With the current industry focus on big data in healthcare, the amount of data created in the next three years is expected to be more than the data created over the past three decades. There’s always a residual risk to privacy in data, and with exponential growth expected, we must explore all techniques we have available to us to minimize risk while absorbing the utility. - Said Jamie Blackport, CEO and Founder of Mirador Analytics. "We're thrilled to work with Syntegra to help them define better industry-standards of synthetic data metrics we hope to be a game-changer in data privacy protection in the future."
Prognos Health and Mirador Analytics Form Strategic Partnership to Streamline Expert Determination for Patient-Level Data
New York, NY (June 22, 2021) — Prognos Health, a leading healthcare analytics platform company, and Mirador Analytics, the leading HIPAA expert determination provider, today announced a strategic partnership to provide Prognos clients with a more streamlined end-to-end HIPAA certification process that reduces risk.
“At Prognos we are committed to maintaining the highest level of privacy and security for our data and our technology. This partnership with Mirador is an extension of that promise,” said Jason Bhan, MD, co-founder and chief medical officer, Prognos Health. “By working with Mirador to integrate their leading expert determination services and support into our prognosFACTORⓇ platform, our clients can be assured that our analytics or data purchase options on our marketplace are fully de-identified and compliant with HIPAA privacy regulations.”
By partnering with Mirador Analytics, Prognos is able to utilize a suite of programmatic tests to assess the risk of re-identification in healthcare datasets, tools to determine dataset compliance, and have access to an automated approach to removing elements that present any potential risk of re-identification.
“At Mirador, we understand that organizations need more agile access and greater value from healthcare data and so we help them to innovate and improve care quality without compromising compliance and patient confidentiality. We’re excited to partner with Prognos because they have something unique – the ability to link lab test result data with other more traditional and emerging datasets at scale,” shared Jamie Blackport, founder and chief executive officer, Mirador Analytics. “We look forward to expanding our partnership to accelerate our expert-led risk monitoring automation processes within the Prognos environment.”
To continue improving scalability, Prognos Health and Mirador Analytics seek to further develop the partnership in the future to provide an even faster, more automated process using a SaaS model embedded within Prognos Health’s prognosFACTOR platform.
Life after the COVID-19 outbreak
Our team has celebrated Mirador Day recently with much fun and outdoor activities which they kindly shared with us. They went cycling, camping, and walking; they visited their old universities and friends. Others enjoyed some lovely family time with their kids, both indoors and outdoors.
Our team is the heart of our business; they are our superstars. We are dedicated to protecting them from the risk of infection and helping them stay physically and mentally healthy.
Author: Eszter Vuity
We are thrilled to share the news of the $1m Research Accelerator program announced by the COVID-19 Research Database Consortium today. The fund is available for research teams leveraging real-world data available to inform medical interventions and targeted mitigation policies.
The COVID-19 Research Database, with 1,500 researchers and over 100 studies in progress, is the largest HIPAA-compliant dataset available to public health and policy researchers, enabling them to further their investigations of the direct and indirect effects of the COVID-19 pandemic on population health and economics.
We are grateful to all our partners for making this world-changing opportunity available. Big thank you to AnalyticsIQ, Change Healthcare, Elsevier, Glooko, Health Care Cost Institute, Healthjump, HealthWise Data, Medidata Solutions, Datavant, MUNICH RE US LIFE CORPORATION, Office Ally, Ovation, PointClickCare, QIAGEN, SAS, Snowflake, STATA, Symphony Health, Veradigm, and Eurofins Viracor.
Read press >>
Mirador Analytics Partners with Datavant to Create Step Change in Industry’s Approach to HIPAA De-identification and Certification
Today, Mirador Analytics, the leading HIPAA Expert Determination provider, and Datavant, the leader in helping healthcare organizations safely connect their data while protecting patient privacy, announced a partnership where Mirador Analytics will offer streamlined HIPAA certification services and remediation tools to members of the Datavant ecosystem.
While still having Experts active in performing determinations, the integration of products automates large portions of the certification process, resulting in a much faster end-to-end certification process, while simultaneously protecting data under HIPAA and providing flexibility in which data to preserve.
Under the partnership, Datavant customers who use Mirador’s service receive on-demand certification of new datasets with results returned within 24 hours. The technical integration includes:
“The value of health data is more crucial today than ever before. The huge amounts of data available brings greater privacy risk and there is a concern of bottlenecks in assessing this risk in deidentified data.” said Jamie Blackport, Founder and Chief Executive Officer of Mirador. “Current approaches are either slow, taking months to certify a single new combination of data; or they are generic, assuming that one certified data layout will meet all customer needs which has potential for increased risk and reduces data utility. Through our partnership with Datavant, we are eager to offer the Datavant ecosystem an approach to certification that is fast, simple, risk-reducing, and fit-for-purpose, allowing customers to spend less time focused on the certification process and more time providing valuable analytics and insights on top of de-identified, certified health data.”
“We are thrilled to announce our expanded partnership with Mirador,” said Travis May, Founder and Chief Executive Officer of Datavant. “We have worked with the Mirador team for years, and have been continuously impressed with their ability to provide reliable, high-quality statistical certification at the speed of business. The preservation of patient privacy is critical to the ethical and trusted use of patient data, and we expect that this new partnership will reset the bar for privacy-preservation across the industry -- while allowing more data to be safely connected for patient benefit.”
Media Contact: Jamie Gray, firstname.lastname@example.org
COVID-19 Research Database Announces Over 1,500 Researchers Registered And Over 100 Studies in Progress
The COVID-19 Research Database, a pro-bono initiative led by numerous leading healthcare organizations, including Change Healthcare, Datavant, the Health Care Cost Institute (HCCI), Healthjump, Medidata (a Dassault Systèmes company), Mirador Analytics, Office Ally, SAS, StataCorp, Snowflake, Symphony Health, and Veradigm, today announced that it has over 1,500 researchers registered and over 100 studies underway.
"In a crisis situation, in which the country finds itself without a system for collecting, pooling and linking data, this effort within the private sector is a game changer, and a model for future efforts to solve national clinical and public health challenges," said Dr. Mark Cullen, professor of medicine at Stanford and chair of the Scientific Steering Committee.
Researchers from more than 350 different institutions have registered, including all of the country's 30 top medical schools, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, and the National Institutes of Health. Research groups are working on studies ranging from optimal policy responses to the pandemic to how the pandemic has changed the provision of non-COVID-19 related services.
Sample publications have investigated:
"The type of near-real-time, high-frequency and comprehensive data that researchers can access through the COVID-19 Research Database is unprecedented," said Dr. Kosali Simon, the Herman B. Wells Endowed Professor in health economics at the O'Neill School of Public and Environmental Affairs at Indiana University. "It's enabling research that would otherwise have taken years to complete, for guiding policy and practitioner decisions that needed to be made yesterday."
In addition, the database effort has identified and implemented new ways to better utilize real-world data, which will continue to be valuable post-pandemic and in studying other diseases. The database effort has introduced an innovative new data solution allowing many data sets to be joined together without compromising patient privacy. This will create longer and richer longitudinal histories, which enable researchers to better understand the impacts of the current pandemic and the long-term impacts for patients' health. Mirador Analytics provided the expert determination services for the creation of the data solution along with Medidata, a Dassault Systemes company, which built the data architecture and provisioned environment to enable researchers to access the database. The Health Care Cost Institute will continue to manage the researcher application process and data governance for the effort.
Organizations participating in the COVID-19 Research Database include AnalyticsIQ, Arcadia.io, Berkeley Research Group, Change Healthcare, Datavant, Elsevier, Eurofins Viracor, Glooko, Health Care Cost Institute, Healthjump, HealthWise Data, Helix, Medidata, a Dassault Systemes company, Mirador Analytics, Munich Re Life US, Office Ally, Ovation, Panalgo, Parexel, PointClickCare, Prognos Health, QIAGEN, SAS, Snowflake, StataCorp, Sumitomo Dainippon Pharma, Symphony Health, Veradigm, and Verana Health.
Read Press Release >>
Source: Datavant / Newswire
DeepIntent Adtech Solution First To Meld Differential Privacy & Machine Learning To Reach Specific Patients In A Privacy-Safe Way
Marketing technology company, DeepIntent, today announced general availability of Patient Modeled Audiences. The patent-pending, end-to-end advertising solution is HIPAA-certified and is the first to effectively combine differential privacy and machine learning to reach specific patient populations in a privacy-safe way. The solution delivers timely and relevant health and treatment information to patients, a capability that's been particularly important during COVID-19.
Patient Modeled Audience's data-driven approach significantly improves advertisers' ability to reach clinically-relevant audiences—in fact, an independent thirty-day test of twelve adtech solutions* found that DeepIntent's audience quality scores were 25% higher than others in the group.
To date, healthcare organizations have been limited in the ways they can reach patients with specific diagnoses, often having to choose either accuracy (using opted-in consent-based patient targeting) or scale (using highly inefficient third-party data segments). Patient Modeled Audiences is the first adtech solution to deliver both by anonymizing healthcare data and extracting only the information needed to segment and reach specific patient audiences with speed and precision.
"Our clients are seeing unprecedented campaign performance, indicating that the right patients are receiving the information they need to make more informed decisions about their health," said DeepIntent Co-Founder and CEO, Chris Paquette. "It also proves that with Patient Modeled Audiences, marketers no longer need to choose between accuracy and scale. By combining emerging privacy technologies with machine learning built specifically for healthcare, DeepIntent closed this divide while mathematically guaranteeing HIPAA compliance."
DeepIntent has partnered with privacy experts, Mirador Analytics, to ensure the data employed in Patient Modelled Audiences meets the most stringent privacy measures.
Read Press Release >>
Source: PR Newswire
Life science companies combine to form COVID-19 research database
A consortium of leading healthcare companies today announced the launch of the COVID-19 Research Database, a secure repository of HIPAA-compliant, de-identified and limited patient-level data sets made available to public health and policy researchers to extract insights to help combat the COVID-19 pandemic.
The database is a pro bono, cross-industry collaboration. Collaborators include Advarra, Aetion, AnalyticsIQ, Arcadia.io, Berkeley Research Group, BHE, Change Healthcare, Datavant, Elsevier, Glooko, Health Care Cost Institute, Healthjump, Helix, Medidata (a Dassault Systèmes company), Mirador Analytics, Munich Re Life US, Office Ally, OMNY, Parexel, Prognos Health, QIAGEN, SAS, Snowflake, Sumitomo Dainippon Pharma, Symphony Health, Veradigm, and Verana Health.
Researchers and policymakers seeking to better understand the COVID-19 pandemic have faced challenges because data relevant for this research are hard to access, fragmented and limited in their ability to answer critical research questions. The COVID-19 Research Database contains HIPAA-compliant, de-identified and limited, longitudinal, patient-level data sets from a consortium of institutions and organizations. It comprises a large, diverse repository of real-world data, including medical claims, pharmacy claims, electronic health records, and demographic data. In addition to the underlying data, the repository integrates privacy-preserving patient linking technology and statistical certification, connecting data sources in a HIPAA-compliant manner to provide a more complete view of the patient journey. Researchers can access the COVID-19 Research Database via an analytic platform, enabling them to conduct large-scale studies while protecting patient privacy.
Read Press Release >>
Source: PRNewswire / Fierce Biotech
Swoop Granted Patent for Privacy-by-Design Data Processing Techniques
Swoop, a Cambridge-based health technology company, today announced they have been granted a patent for their privacy-safe sensitive data processing techniques. The patent leaves the organization uniquely positioned to ingest, manipulate and analyze sensitive data, such as health data, in a way that ensures the protection of the privacy of individuals while also ensuring the accuracy of its AI models and the positive impact they have on patient outcomes and healthcare costs.
This patent, and the core concept of Privacy by Design that it embraces, is a recognition that historical perspectives on privacy can and should evolve to embed privacy foundationally into an organizations' architectural DNA in the rapidly evolving privacy environment of today.
"Though HIPAA has had an enduring institutional legacy as a privacy law, we are seeing that, in today's dynamic ecosystem, the regulatory environment is rapidly evolving. GDPR, CCPA, and self-regulatory bodies like the NAI, are all reconciling what consumer and patient privacy looks like in the digital world," says Swoop co-founder and CTO Simeon Simeonov. "Our invention embodies the concept of Privacy by Design. Not only do we embrace privacy as the default state, but our patent outlines a de facto privacy architecture that maintains strict compliance as these and other new privacy regulations and self-regulatory best practices develop."
The patent, titled "High-Accuracy Data Processing and Machine Learning Techniques for Sensitive Data," enables systematic compliance with the Health Insurance Portability and Accountability Act (HIPAA), the California Consumer Privacy Act (CCPA), the Network Advertising Initiative's 2020 Code of Conduct, and the General Data Protection Regulation (GDPR).
"We specialize in protecting the privacy of individuals by performing disclosure risk assessments on our clients' healthcare datasets," says Jamie Blackport, CEO and Co-Founder of Mirador Analytics, which handles Swoop's HIPAA compliance. "While working with Swoop to ensure HIPAA compliance, their commitment to developing systems with privacy in mind was clear and we have been impressed with the paramount importance they have placed on patient privacy."
Read Press Release >>
Source: PR Newswire